On February 14, Andon Health Co.Ltd(002432) announced that due to the incomplete disclosure of information, Tianjin Securities Regulatory Bureau decided to take the supervision and management measures of supervision conversation with the chairman and Secretary of the company.
The company said it would actively rectify, seriously summarize and draw lessons in strict accordance with regulatory requirements. However, the company said that the above administrative supervision measures had no significant impact on the company’s operation.
On February 14, the company’s share price fell 6.64% to 55.15 yuan / share.
Recently, the stock price of Andon Health Co.Ltd(002432) which had risen sharply in a row has been adjusted continuously. From January 18 to February 14, the company’s stock price has fallen 33.4% from the high point of 88.88 yuan / share.
due to incomplete disclosure
the chairman and the Secretary of the company were taken to have a regulatory conversation
Andon Health Co.Ltd(002432) according to the announcement, the company recently received the decision on administrative supervision measures and the decision on taking supervision talk measures against Liu Yi and Wu Tong from Tianjin Securities Regulatory Bureau.
According to the decision, on January 7, 2022, Andon Health Co.Ltd(002432) disclosed that the company received the performance test report of the Radx project of the National Institutes of Health (NIH) on the household self-test OTC kit of ihealth covid-19 antigen against Omicron mutant virus arranged by the FDA on January 5, 2022 Beijing time, The report also said that “the ihealth-covid-19 antigen rapid test detected 100% of Omicron active virus samples with a maximum CT value of 21.59 (n = 5)”.
On January 15, 2022, when replying to the letter of concern from Shenzhen Stock Exchange, the company said that “100% of Omicron active virus samples with a maximum CT value of 21.59 (n = 5) were detected in the experiment” previously disclosed by the company, in which “maximum” means that samples less than or equal to 21.59 can be detected 100%, and samples greater than 21.59 cannot be detected 100%, It also said that “the positive detection rate of all samples in the experimental group: when the CT value is ≤ 21.59, it can be detected completely, when the CT value is 22.86, it can be detected 60%, and when the CT value is ≥ 23.87, it can not be detected at all.”
According to the decision, Andon Health Co.Ltd(002432) only disclosed some successful test results on January 7, 2022, but did not disclose all the test results, and the disclosure information was incomplete.
According to the decision, Liu Yi, as the chairman and general manager of Andon Health Co.Ltd(002432) and Wu Tong, as the Secretary of Andon Health Co.Ltd(002432) board of directors, bear the main responsibility for the integrity of information disclosure in the interim report of listed companies. During their term of office, they failed to faithfully and diligently perform their duties, violating the provisions of Article 4 of the measures for the administration of information disclosure of listed companies. According to the provisions of articles 51 and 52 of the measures for the administration of information disclosure of listed companies, Tianjin Securities Regulatory Bureau decided to take the supervision and administration measures for the two people’s regulatory conversation, and asked them to bring valid ID cards to Tianjin Securities Regulatory Bureau for regulatory conversation before February 18, 2022.
Andon Health Co.Ltd(002432) said that the company and relevant personnel attach great importance to the above administrative supervision measures, and will actively rectify in strict accordance with the supervision requirements, carefully summarize and draw lessons, strengthen the learning of relevant personnel on securities laws and regulations, and strengthen the awareness of standardized operation; Strengthen internal control and information disclosure management, effectively improve the standard operation level and information disclosure quality of the company, safeguard the interests of the company and all shareholders, and promote the healthy, stable and sustainable development of the company. The above administrative supervision measures have no significant impact on the operation of the company.
responding to institutional concerns
In response to the problem of whether the company’s current antigen self-test products have excess capacity and how to evolve in the future, Andon Health Co.Ltd(002432) responded in the record of investor relations activities disclosed on February 14 that the biggest influencing variables of the demand for antigen self-test products in the future are the epidemic situation and the virus mutation path itself. The government’s control measures first affect the proportion of different sales channels of the company, whether it is retail or government orders, whether it is reimbursed through commercial insurance after people buy it or distributed by the government free of charge. Secondly, whether there will be a phased rebound of the epidemic after the relaxation of control measures, or if schools or enterprises require students and employees to conduct regular tests and the use of covid-19 treatment drugs in the process of full resumption of work and production, they may have an impact on the demand. In addition, the U.S. government has published the bidding information of the second batch of 500 million kits on its official procurement publicity website, which is said to prepare for its expected demand. This information can be queried through the public website. The company said that its supply chain and product system are capable of responding to changes in demand.
The company said that the continuous situation of covid-19 had a profound impact on people’s lifestyle and habits. One of them is to accept and get used to using IVD self-test products. It is not only for covid-19 test, but also optimistic about the market opportunities of follow-up family self-test products and household medical and health products.
The company said that from the perspective of the combination of convenient and fast detection methods and convenient and effective treatment methods, the market of self-test kit and covid-19 drugs may promote each other. More testing may increase the demand for drugs, and effective treatment can enhance the public’s willingness to test (there are drugs to cure), so that the demand for testing continues.
the cumulative decline from the high point is more than 33%
On the evening of November 7, 2021, Andon Health Co.Ltd(002432) announced that the U.S. subsidiary ihealth home covid-19 self-test kit had obtained the emergency use authorization (EUA) of the U.S. Food and Drug Administration (FDA). After that, the company’s share price sat on the “helicopter” and continued to rise, hitting record highs. At that time, it was called the “demon king” by investors.
After the beginning of 2022, the company’s share price continued to rise sharply. From January 11 to January 17, the company closed five consecutive boards. From the lowest 5.8 yuan on October 29, 2021 to the highest 88.88 yuan on January 18 this year, the cumulative increase of Andon Health Co.Ltd(002432) in two and a half months exceeded 14 times.
Since then, the company’s share price has risen by nearly 40.88% since January 26, and the company’s share price has fallen by nearly 40.88% since January 26.
On the morning of January 27, the company announced that the order of covid-19 kit in the United States was added. Boosted by the news, Andon Health Co.Ltd(002432) share price stopped falling and rebounded. From January 28 to February 10, the company’s share price achieved a short-term rebound, with a cumulative rise of more than 20%.
On February 11, the company’s share price fell again, falling by more than 9%. From January 18 to February 14, the company’s share price fell 33.4% from the high point of 88.88 yuan / share.
